A controlled trial of buprenorphine treatment for opioid dependence

R. E. Johnson, J. H. Jaffe and P. J. Fudala
Addiction Research Center, National Institute on Drug Abuse, Baltimore, Md.

OBJECTIVE--To assess the efficacy of buprenorphine for short-term maintenance/detoxification. DESIGN--A randomized, double-blind, parallel group study comparing buprenorphine, 8 mg/d, methadone, 60 mg/d, and methadone, 20 mg/d, in a 17-week maintenance phase followed by an 8-week detoxification phase. SETTING--Outpatient facilities at the Addiction Research Center, Baltimore, Md. PATIENTS--One hundred sixty-two volunteers seeking treatment for opioid dependence. INTERVENTION--In addition to the medication, counseling using a relapse prevention model was offered but not required. PRIMARY OUTCOME MEASURES--Retention time in treatment, urine samples negative for opioids, and failure to maintain abstinence. RESULTS--Throughout the maintenance phase, retention rates were significantly greater for buprenorphine (42%) than for methadone, 20 mg/d (20%, P less than .04); the percentage of urine samples negative for opioids was significantly greater for buprenorphine (53%, P less than .001) and methadone, 60 mg/d (44%, P less than .04), than for methadone, 20 mg/d (29%). Failure to maintain abstinence during the maintenance phase was significantly greater for methadone, 20 mg/d, than for buprenorphine (P less than .03). During the detoxification phase, no differences were observed between groups with respect to urine samples negative for opioids. For the entire 25 weeks, retention rates for buprenorphine (30%, P less than .01) and methadone, 60 mg/d (20%, P less than .05), were significantly greater than for methadone, 20 mg/d (6%). All treatments were well tolerated, with similar profiles of self-reported adverse effects. The percentages of patients who received counseling did not differ between groups. CONCLUSIONS--Buprenorphine was as effective as methadone, 60 mg/d, and both were superior to methadone, 20 mg/d, in reducing illicit opioid use and maintaining patients in treatment for 25 weeks.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

A 50-Year-Old Woman Addicted to Heroin: Review of Treatment of Heroin Addiction
O'Brien
JAMA 2008;300:314-321.
ABSTRACT | FULL TEXT  

QT-Interval Effects of Methadone, Levomethadyl, and Buprenorphine in a Randomized Trial
Wedam et al.
Arch Intern Med 2007;167:2469-2475.
ABSTRACT | FULL TEXT  

Treating Opioid Addiction With Buprenorphine-Naloxone in Community-Based Primary Care Settings
Mintzer et al.
Ann Fam Med 2007;5:146-150.
ABSTRACT | FULL TEXT  

Buprenorphine for the treatment of opioid dependence
Boothby and Doering
Am J Health Syst Pharm 2007;64:266-272.
ABSTRACT | FULL TEXT  

Injectable, Sustained-Release Naltrexone for the Treatment of Opioid Dependence: A Randomized, Placebo-Controlled Trial
Comer et al.
Arch Gen Psychiatry 2006;63:210-218.
ABSTRACT | FULL TEXT  

Pharmacokinetics and Pharmacodynamics of Multiple Sublingual Buprenorphine Tablets in Dose-Escalation Trials
Ciraulo et al.
J Clin Pharmacol 2006;46:179-192.
ABSTRACT | FULL TEXT  

Comparison of Pharmacological Treatments for Opioid-Dependent Adolescents: A Randomized Controlled Trial
Marsch et al.
Arch Gen Psychiatry 2005;62:1157-1164.
ABSTRACT | FULL TEXT  

Medication Development for Addictive Disorders: The State of the Science
Vocci et al.
Am. J. Psychiatry 2005;162:1432-1440.
ABSTRACT | FULL TEXT  

Plasma Testosterone and Sexual Function in Men Receiving Buprenorphine Maintenance for Opioid Dependence
Bliesener et al.
J. Clin. Endocrinol. Metab. 2005;90:203-206.
ABSTRACT | FULL TEXT  

Treating Opioid Dependence: Growing Implications for Primary Care
Krantz and Mehler
Arch Intern Med 2004;164:277-288.
ABSTRACT | FULL TEXT  

Office-Based Treatment of Opiate Addiction with a Sublingual-Tablet Formulation of Buprenorphine and Naloxone
Fudala et al.
NEJM 2003;349:949-958.
ABSTRACT | FULL TEXT  

Intravenous Buprenorphine Self-Administration by Detoxified Heroin Abusers
Comer et al.
J. Pharmacol. Exp. Ther. 2002;301:266-276.
ABSTRACT | FULL TEXT  

Transplacental Transfer and Metabolism of Buprenorphine
Nanovskaya et al.
J. Pharmacol. Exp. Ther. 2002;300:26-33.
ABSTRACT | FULL TEXT  

Buprenorphine: "Field Trials" of a New Drug
Agar et al.
Qual Health Res 2001;11:69-84.
ABSTRACT  

A Comparison of Levomethadyl Acetate, Buprenorphine, and Methadone for Opioid Dependence
Johnson et al.
NEJM 2000;343:1290-1297.
ABSTRACT | FULL TEXT  

Pharmacologic Treatment of Heroin-Dependent Patients
O'Connor and Fiellin
ANN INTERN MED 2000;133:40-54.
ABSTRACT | FULL TEXT  

Treatment for Opioid Dependence: Quality and Access
Rounsaville and Kosten
JAMA 2000;283:1337-1339.
FULL TEXT  

Desipramine in Opioid-Dependent Cocaine Abusers Maintained on Buprenorphine vs Methadone
Oliveto et al.
Arch Gen Psychiatry 1999;56:812-820.
ABSTRACT | FULL TEXT  

Moderate- vs High-Dose Methadone in the Treatment of Opioid Dependence: A Randomized Trial
Strain et al.
JAMA 1999;281:1000-1005.
ABSTRACT | FULL TEXT  

The Effects of Buprenorphine on Self-administration of Cocaine and Heroin "Speedball" Combinations and Heroin Alone by Rhesus Monkeys
Mello and Negus
J. Pharmacol. Exp. Ther. 1998;285:444-456.
ABSTRACT | FULL TEXT  

Management of Cocaine Abuse and Dependence
Mendelson and Mello
NEJM 1996;334:965-972.
FULL TEXT  

Fortnightly Review: Methadone maintenance treatment in opiate dependence: a review
Farrell et al.
BMJ 1994;309:997-1001.
FULL TEXT  

Medical Care for Injection-Drug Users with Human Immunodeficiency Virus Infection
O'Connor et al.
NEJM 1994;331:450-459.
FULL TEXT  

BUPRENORPHINE FOR OPIOID ADDICTION
JWatch General 1992;1992:4-4.
FULL TEXT